✦ LIBER ✦

Loreclezole monotherapy in patients with partial seizures

✍ Scribed by Th.W Rentmeester; J.A.R.J Hulsman

Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 447 KB
Volume: 11
Category: Article
ISSN: 0920-1211
DOI: 10.1016/0920-1211(92)90048-x

No coin nor oath required. For personal study only.

✦ Synopsis

Monotherapy is preferable in the treatment of epilepsy; a new antiepileptic drug has to be checked on its efficacy in monotherapy. In this study patients who had successfully been treated with loreclezole in previous studies were gradually withdrawn from their antiepileptic comedication. Nine patients participated in the study. Reduction of comedication was well tolerated in all, no serious side effects occurred. In 6 patients seizure frequency remained unchanged, i.e., within 50% limits. Two patients experienced a clear increase in seizure frequency. In 2 patients reintroduction of a second antiepileptic drug was mandatory. One patient experienced a further reduction in seizure frequency when monotherapy was reached. This observation indicates efficacy of loreclezole, also in monotherapy.

📜 SIMILAR VOLUMES

Felbamate monotherapy: Controlled trial

Felbamate monotherapy: Controlled trial in patients with partial onset seizures

✍ Rajesh Sachdeo; Lynn D. Kramer; Alberto Rosenberg; Dr. Satinder Sachdeo 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 658 KB

Felbamate (FBM) monotherapy was evaluated in 44 patients with uncontrolled partial onset seizures in a unique, single-center, randomized, double-blind, parallel-group trial. During the 56-day baseline peripd, patients were required to have at least 8 seizures and to be receiving only one standard an

A double-blind, placebo-controlled evalu

A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures

✍ T Rentmeester; A Janssen; J Hulsman; F Scholtes; B van der Kleij; J Overweg; J M 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 655 KB

Sixty-two patients with uncontrolled partial seizures participated in a 12-week, double-blind, placebo-controlled add-on-trial. Thirty-two patients received loreclezole and 30 a placebo as add-on therapy. Loreclezole was targeted at a plasma level of 1-2 mg/l. In spite of an antiepileptic therapy, u

Nocturnal plasma prolactin rise in patie

Nocturnal plasma prolactin rise in patients with complex partial seizures

✍ Dr. Majid Molaie; Antonio Culebras; Myron Miller 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 410 KB

Long-term evaluation of the efficacy and

Long-term evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures: a 1-year open follow-up

✍ T. Rentmeester; A. Janssen; J. Hulsman; F. Scholtes; B. van der Kleij; J. Overwe 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 534 KB

The effect and safety of loreclezole were evaluated during a long-term follow-up trial targeting higher plasma concentrations than those of the preceding controlled trial. The result is better than in the double-blind trial, in which loreclezole doses were administered to reach plasma concentrations

Extratemporal atrophy in patients with c

Extratemporal atrophy in patients with complex partial seizures of left temporal origin

✍ C. Decarli; Junko Hatta; Shahram Fazilat; Shahin Fazilat; W. D. Gaillard; Dr Wil 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 633 KB

Seizures in patients with trisomy 21

✍ Romano, Corrado ;Tiné, Alessandra ;Fazio, Grazia ;Rizzo, Renata ;Colognola, Rosa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB 👁 2 views